China Resources Pharmaceutical Group Limited is an enterprise group integrating drug research and development, manufacturing and distribution. It is one of the seven core strategic business units of China Resources (Group) Co., Ltd.
In 2012 (the year of Renchen), China Resources Pharmaceutical achieved a turnover of HK$98.6 billion, an operating profit of HK$6.16 billion, and total assets of HK$85.6 billion. The overall scale ranked among the top three in China's pharmaceutical industry.
China Resources Pharmaceutical provides products and services across 29 provinces (autonomous regions and municipalities) across the country. It has a strong industrial foundation and leading advantages in pharmaceutical manufacturing and pharmaceutical distribution, and is committed to creating synergy across the entire industry chain. Development platform. China Resources Pharmaceuticals has a modern production base, distribution center and high-level R&D center. It specializes in proprietary Chinese medicines, non-fried Chinese medicines, chemically synthesized drugs, biological drugs, natural drugs, API intermediates, nutritional health products, pharmaceutical equipment, pharmaceutical distribution, etc. It provides products and services to patients and society in multiple fields, and has more than 80 GMP-certified modern production lines. Among them, it is a leader in China in the fields of cardiovascular, large-scale infusion, reproductive health, gene therapy, natural medicine, proprietary Chinese medicine, and medical devices.
It has more than 20 products with sales exceeding 100 million Hong Kong dollars, and 2 products with sales exceeding 1 billion Hong Kong dollars (999 Ganmao Ling, Dong'e Ejiao Block). The total sales of products with sales exceeding 100 million Hong Kong dollars exceed 11 billion Hong Kong dollars. It has "China's famous trademarks" such as "999", "Shuanghe", "Seco", "Donga" and "Yu Ting". The "999" brand has also been selected into the top 50 most valuable brands in China twice. "Donga Ejiao" " and other brands were rated as "China's 500 Most Valuable Brands".
Focusing on the long-term development in the future, China Resources Pharmaceuticals has started to invest in the construction of a large-scale biopharmaceutical industrial park project in Beijing with international advanced level and positioned for innovative R&D and high-end manufacturing. It is integrating its R&D resources and setting up an innovative The incubation platform unifies the planning, organization and implementation of the full-process business development system of R&D, innovation, incubation and industrialization, organically combines development strategy, market competition and operation management, and continuously enhances the core competitiveness and market competitiveness of China Resources Pharmaceuticals.
China Resources Pharmaceuticals will adhere to China Resources Group’s corporate values ??of “honesty and trustworthiness, performance-oriented, customer first, and gratitude in return” and its corporate spirit of “pragmatism, passion, professionalism, and innovation”, with the lofty goal of improving the quality of human life. Mission: Committed to becoming a leader in China's pharmaceutical industry and contributing to human health.